How to treat MDS without stem cell transplantation.
Although allogeneic hematopoietic cell transplantation (HCT) is the only proven curative treatment for myelodysplastic syndromes (MDS), it is only used to treat a minority of MDS patients. The majority of patients are too old or suffer from comorbidities rendering allogeneic HCT too risky. Alternative treatment strategies for patients with higher risk MDS try to alter the natural course of disease by preventing or delaying leukemic transformation. In patients with lower risk MDS, treatment is mainly focused on maintaining or improving the quality of life.
Gattermann
Norbert
N
Klinik für Hämatologie, Onkologie u. klinische Immunology Heinrich-Heine-Universität Moorenstr. 5D-40225 Düsseldorf, Germany. gattermann@med.uni-duesseldorf.de
D000970:Antineoplastic Agents / Q000627:therapeutic use; D016913:Blood Component Transfusion; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007502:Iron Chelating Agents / Q000627:therapeutic use; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000628:therapy
D000970:Antineoplastic Agents; D016298:Hematopoietic Cell Growth Factors; D007502:Iron Chelating Agents